Health Canada’s ability to monitor the safety of marketed health products depends on healthcare professionals and consumers reporting adverse reactions and medical device incidents. Any case of graft rejection or other serious or unexpected adverse reactions in patients receiving tacrolimus should be reported to the appropriate manufacturer (see “Products affected”) or Health Canada.
Accord Healthcare Inc.
3535 Saint-Charles Blvd, Suite 704
Kirkland, Québec, H9H 5B9
Tel : +44 (0)208 901 3370
Paladin Labs Inc.
100 Boulevard Alexis-Nihon, Suite 600 Montréal, Québec, H4M 2P2
Tel : 1-888-867-7426
Apotex Inc.
150 Signet Drive
Toronto, Ontario, M9L 1T9
Tel : 1-800-667-4708
Sandoz Canada
110 De Lauzon
Boucherville, Québec, J4B 1E6
Tel : 1-800-343-8839
Astellas Pharma Canada, Inc.
675 Cochrane Drive, Suite 500, West Tower Markham, Ontario, L3R 0B8
Tel : 1-888-338-1824
Sun Pharma Canada Inc.
126 East Drive
Brampton, Onatrio, L6T 1C1
Tel: 1-866-840-1340
Jamp Pharma Corporation
1310 Nobel
Boucherville, Québec, J4B 5H3
Tel : 1-866-399-9091
To correct your mailing address or fax number, contact the appropriate manufacturer. You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
-
Calling toll-free at 1-866-234-2345; or
-
Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate
E-mail:
mhpd-dpsc@canada.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Original signed by: Pranav Pandya, MPharm
Director, Regulatory Affairs and Quality Assurance
Accord Healthcare Inc.
Colin D'Cunha, MBBS, MHSc, FRCPC
Director, Global Medical Affairs
Apotex Inc.
Perry Proskos, BSc (Hons)
Director, Regulatory Affairs and Quality Assurance
Astellas Pharma Canada Inc.
Patrizia Franco
Senior Director, Regulatory Affairs
Jamp Pharma Corporation
Randy Levitt, PhD
Director, Pharmacovigilance and Medical Affairs
Paladin Labs Inc.
Mauricio Ede, MD, PhD
Chief Medical and Scientific Officer
Sandoz Canada
Neha Rana, PharmD
Director, Drug Safety
Sun Pharma Canada Inc. (formerly Ranbaxy Pharmaceuticals Canada Inc.)
Reference
-
Prograf and Advagraf Mix-up [Internet]. Toronto: Institute for Safe Medication Practices Canada; 2009 Jun. [accessed July 4 2019 ]. Available from: http://www.ismp-canada.org/download/safetyBulletins/ISMPCSB2009-5-PrografandAdvagrafMix-up.pdf